R-Biopharm AG of Darmstadt at MEDICA 2019 in Düsseldorf -- COMPAMED Trade Fair
Manage stand orders
Select Option
Manufacturers Trader Service

R-Biopharm AG

An der neuen Bergstr. 17, 64297 Darmstadt
Germany
Telephone +49 6151 8102-0
Fax +49 6151 8102-40
info@r-biopharm.de

Hall map

MEDICA 2019 hall map (Hall 3): stand B20

Fairground map

MEDICA 2019 fairground map: Hall 3

Our range of products

Product categories

  • 02  Laboratory Technology
  • 02.01  Analyser systems / equipment

Analyser systems / equipment

  • 02  Laboratory Technology
  • 02.17  Pipetting devices, pipetting equipment

Pipetting devices, pipetting equipment

  • 02  Laboratory Technology
  • 02.20  Shaking and mixing units

Shaking and mixing units

  • 03  Diagnostic Tests
  • 03.01  Clinical chemistry
  • 03.01.04  Rapid tests in clinical chemistry

Rapid tests in clinical chemistry

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing
  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.02  Diagnostic rapid tests
  • 03  Diagnostic Tests
  • 03.04  Microbiology testing
  • 03.04.01  Bacteriology testing in microbiology

Bacteriology testing in microbiology

  • 03  Diagnostic Tests
  • 03.04  Microbiology testing
  • 03.04.02  Parasitology testing in microbiology

Parasitology testing in microbiology

  • 03  Diagnostic Tests
  • 03.04  Microbiology testing
  • 03.04.03  Rapid tests in microbiology

Rapid tests in microbiology

  • 03  Diagnostic Tests
  • 03.05  Infectious immunology testing
  • 03.05.02  Microbiological diagnosis, virology, equipment and systems for

Microbiological diagnosis, virology, equipment and systems for

  • 03  Diagnostic Tests
  • 03.05  Infectious immunology testing
  • 03.05.03  Other infectious immunology testing

Other infectious immunology testing

  • 03  Diagnostic Tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.03  Polymerase chain reaction (PCR)

Polymerase chain reaction (PCR)

  • 03  Diagnostic Tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.04  Other molecular diagnostics testing

Other molecular diagnostics testing

Our products

Product category: Immuno assay testing

ThunderBolt®

We offer different automation solutions for your lab´s demand. The ThunderBolt® is a convenient instrument for automated ELISA processing.

Automated ELISA processing on a small foot print
Due to time and cost reasons, automation plays an increasingly important role in laboratories. Each diagnostic has specific needs and demands that must be adapted to each laboratory‘s requirements. This is where R-Biopharm AG comes in with its solutions for automation.

In cooperation with our partner GSD, an expert in ELISA automation, we brought together our expertise in assay and instrumentation on the ThunderBolt®. The ThunderBolt® is an ELISA platform for small to medium sample throughput for different laboratory requirements, which perfectly works with our RIDASCREEN® ELISA.

Experience the R-Biopharm ELISA automation concept with the new ThunderBolt®
The ThunderBolt® system features:

Powerful automation: Walk-away processing of virtually any EIA or CLIA assay – the ThunderBolt® offers automation features previously reserved for instruments many times the price and size. Streamline your workflow with fully automated processing, reading and reporting of results.
Ultimate flexibility: Premium content, expert installation – leverage a vast network of premium assays sourced from the best manufacturers around the globe. Program the ThunderBolt® to run virtually any EIA or CLIA assay with up to eight different protocols in a single batch.
Innovations abound: Patented features mean dramatic benefits – with a host of patented features, ThunderBolt® automation gives your lab the speed and quality you demand.
Compact & capable: Reclaim bench space, maintain capability – even as the smallest and lightest instrument in its class, the ThunderBolt® packs a punch. Recover bench-top real estate occupied by bulky, outdated equipment by upgrading to ThunderBolt® automation. With a 2’ x 2’ footprint, and weighing in at a mere 65 pounds, the ThunderBolt® can easily be moved by one person.
Intuitive, adaptable software: Easy operation, in-depth analysis – just like the hardware, the ThunderBolt® software provides all the features your lab requires, and more. Intuitive operation allows for easy training and ongoing use. The Test Designer allows for exceptional assay protocol adherence, and the Report Generator offers numerous reporting and analysis options that can be tailored to your lab’s needs.

More Less

Product category: Immuno assay testing

GEMINI

Fully automated 2-plate ELISA system for our RIDASCREEN® ELISA.

More Less

Product category: Immuno assay testing

DS2™

Fully automated 2-plate ELISA system for our RIDASCREEN® ELISA.

More Less

Product category: Immuno assay testing

DSX™

Fully automated 4-plate ELISA system for our RIDASCREEN® ELISA.

More Less

Product category: Immuno assay testing

Agility®

Fully automated 12-plate ELISA system for our RIDASCREEN® ELISA.

More Less

Product category: Diagnostic rapid tests

RIDA®QUICK Helicobacter

Intended use: 

For in vitro diagnostic use. RIDA®QUICK Helicobacter is an immunochromatographic rapid test (ICT) for the qualitative detection of Helicobacter pylori-specific antigen in human stool specimens.

General information:
In 1984, Warren and Marshall discovered the Gram-negative spiral-shaped bacterium Helicobacter pylori in the mucosa of the gastric antrum and corpus in patients with confirmed gastritis and peptic ulcers of the duodenum. Nowadays Helicobacter pylori is recognized as causative agent of gastrointestinal diseases like chronic gastritis, gastric ulcers and gastric cancer. In 1994, the World Health Organization (WHO) classified Helicobacter pylori as a group I carcinogen and inducer of gastric cancer.

The global prevalence of Helicobacter pylori infections in humans exceeds 50 %, but can greatly differ from country to country: Helicobacter pylori infection is more common in developing countries than in higher developed countries. The differences in Helicobacter pylori prevalence are caused by multiple factors, e.g. ethnicity and socioeconomic characteristics. The highest prevalence of Helicobacter pylori infection is observed in the older age group and in close living communities.

The clinical presentation of Helicobacter pylori infection ranges from lifelong asymptomatic gastritis to gastrointestinal malignancy. If an Helicobacter pylori infection becomes symptomatic, there will be no typical health problems. Unspecific symptoms of an unrecognized Helicobacter pylori infection are: epigastric pain, right-hand epigastralgia, abdominal fullness, feeling of pressure, acid reflux and ructus.

Only diagnostic testing will give information on the Helicobacter pylori infection status.

More Less

Product category: Diagnostic rapid tests

RIDA®QUICK ADM Monitoring

Intended use:
For in-vitro diagnostics. This test is a lateral flow immunochromatographic assay for the quantitative detection of adalimumab (ADM, Humira®) in human serum and plasma.

General information:

The lateral flow assay RIDA®QUICK ADM Monitoring is a rapid assay, which allows for the quantitative determination of adalimumab trough levels (TLs) within 20 minutes. It facilitates the use of therapeutic drug monitoring (TDM) in hospitals and infusion centers and the decision making in regards to therapy adaptation.

Fast and reliable drug monitoring of adalimumab (Humira®)
Quantitative lateral flow test
20 minutes time to result
High correlation to RIDASCREEN® ADM Monitoring due to identical monoclonal antibody (MA-ADM40D8)
25 test cassettes per package
2 controls available as accessory

More Less

Product category: Diagnostic rapid tests

RIDA®QUICK Rota/Adeno/Noro Combi

Intended use:
The RIDA®QUICK Rota/Adeno/Noro Combi is a single step immunochromatographic lateral flow assay for the differential qualitative detection of Rotavirus, Adenovirus and Norovirus of Genogroups I and II in human stool specimen.

General information:
Rotavirus is a double stranded RNA virus belonging to the Reoviridae family. They are viruses with a low infective dose and their transmission mechanism is direct contact by one person to another by a faecal-oral route and, less frequently, through contaminated water and food. The Rotavirus is one of the main aetiological agents of acute gastroenteritis in the whole world and main causal agent of severe dehydration in children between 6 months and 2 years, both in developing countries, where it shows a high mortality, as well as in developed countries. At the age of 5 years, the majority of children (> 95%) have suffered at least one episode of gastroenteritis caused by Rotavirus. Although the development of vaccines is helping to reduce the incidence, only some countries have managed to implement them in their national immunisation program. Rotavirus is classified into seven antigenic serogroups (A to G). Only Groups A, B and C infect humans, with Group A being the causing factor of almost all cases, both in developed countries and in developing countries.

Adenovirus is the third leading cause of viral gastroenteritis in children (10 – 15 %). They can also cause respiratory diseases and depending on the serotype, diarrhoea, conjunctivitis, cystitis, and others. At least 51 adenovirus serotypes have been identified and in all of them the hexon antigen is present. Mainly Serotypes 40 and 41 are associated with gastroenteritis. The main clinical symptom of gastroenteritis caused by adenovirus is diarrhoea, for 9 to 12 days, also occurring with fever and vomiting.

Norovirus is a type of single-stranded, positive-sense RNA virus belonging to the Caliciviridae family. They are highly contagious and their main transmission routes are by person to person contact and by contaminated food / water. The virus usually causes large epidemics in closed communities (hospitals, homes for the elderly, schools, nurseries, restaurants, cruise ships, etc.), where once it has been introduced, infection propagates very rapidly. Several studies demonstrate that Norovirus is the main cause of viral gastroenteritis at any age worldwide and responsible for almost 50% of gastroenteritis outbreaks. Norovirus are grouped in five genogroups (GGI to GGV). The majority of clinical cases are as a result of strains of the genogroups I and II. In general, GI infections are less frequent than GII infections. The virus is classified into genotypes within each genogroup. Up to 19 different genotypes within genogroup II have been decribed. Of them, GII.4 is the most common, representing close to 60 – 80% of the cases worldwide. They are followed by GII.6, GII.1 and GII.3.

More Less

Product category: Diagnostic rapid tests

RIDA®QUICK SCAN II

Intended use:
The RIDA®QUICK SCAN II is a lateral flow test reader for the automated readout of RIDA®QUICK tests from R-Biopharm AG. The RIDA®QUICK SCAN II uses a camera-based system to evaluate high-resolution gray-scale images from RIDA®QUICK tests. The RIDA®QUICK SCAN II is able to obtain quantitative, semi-quantitative and qualitative results by means of a rapid and precise scanning process. RIDA®QUICK tests are carried out by trained laboratory personnel according to the relevant test kit description under the stated conditions for the specific sample material.

Easy and quick quantitative lateral flow measurements
  • High resolution image evaluation
  • Methods and test assay specifications via QR code technology
  • LED self-calibration guarantees signal stability and independent measurements from outside factors like dust
  • Maintenance free
  • Operating time (battery): 6 h
  • Up to 1400 test results can be stored
  • Results as PDF, TXT and XML files
  • LAN connectivity
  • 4.3” color touchscreen
  • Developed for R-Biopharm’s Clinical Diagnostics

More Less

Product category: Diagnostic rapid tests

RIDA®QUICK IFX Monitoring

Intended use:
For in vitro diagnostic use. This test is an enzyme linked immunoassay intended for the quantitative determination of infliximab (IFX, Remicade®) and the biosimilars Remsima®, Flixabi® und Inflectra® in human serum und plasma.

General information:
The lateral flow assay RIDA®QUICK IFX Monitoring is a rapid point-of-care assay, which allows for the quantitative determination of infliximab trough levels (TLs) within 20 minutes. It facilitates the use of therapeutic drug monitoring in hospitals and infusion centers and the decision making in regards to therapy adaptation.

  • Fast and reliable drug monitoring of infliximab and its biosimilars (Remsima® & Inflectra®)
  • Quantitative lateral flow test
  • 20 minutes time to result
  • High correlation to RIDASCREEN® IFX Monitoring due to identical monoclonal antibody (MA-IFXB7)
  • 25 test cassettes per package
  • 2 controls available as accessory

More Less

About us

Company details

R-Biopharm is a leading developer of test solutions for Clinical Diagnostics and Food & Feed Analysis. In both sectors, the R-Biopharm test kits offer high precision and accuracy, key requirements where patient and consumer health is at risk.

R-Biopharm AG was founded in 1988 as a subsidiary of Röhm GmbH in Darmstadt, Germany. In 1991 it was taken over by the present chairman of the board, Dr. Ralf M. Dreher. Since 1996 R-Biopharm’s quality management systems have been certified to the international standards ISO 9001 and in 2003 the company gained ISO 13485 quality management certification. From January 2000 R-Biopharm acquired sole worldwide distribution rights to Enzymatic BioAnalysis, a product developed by Roche (formerly BOEHRINGER Mannheim). In 2002 R-Biopharm took over Rhône Diagnostics Technologies in Scotland, another supplier of mycotoxin test kits, resulting in successful expansion of its position in the food and feed analysis sector. Today the German parent company R-Biopharm is represented by subsidiaries in the USA, UK, Italy, France, Latin America, Brazil, Spain, Belgium, Australia, India, China and the Netherlands, as well as by a worldwide extensive network of more than 120 distributors. In addition, Switzerland and Austria are represented by local Country Managers.

Clinical Diagnostics
In Clinical Diagnostics, R-Biopharm possesses many years of experience, particularly in the field of infectious stool diagnostics as well as in the field of serological infection diagnostics and allergy diagnostics. R-Biopharm has been a successful player worldwide and is constantly developing new and groundbreaking test systems in different areas.

Food & Feed Analysis
In the field of Food & Feed Analysis, R-Biopharm offers an impressive range of immunological, enzymatic and microbiological test kits for the detection of residues, constituents and contaminants. The use of R-Biopharm kits to detect mycotoxins, hormones, antibiotics, food allergens, genetically modified organisms and pathogens is fast, reliable and cost effective.

Nutrition Care
With its own division “Nutrition Care”, R-Biopharm develops innovative concepts for complementary therapies to improve patients’ quality of life. The special diagnostics and customizable programs and services are optimally tuned to one another to find the ideal nutrition and to improve prevention, therapy and wellbeing.

In the field of Clinical Diagnostics as well as in the field of Food & Feed Analysis, the products have been designed and developed primarily for immunoassay platforms. Nonetheless, there is also a great emphasis on other test formats such as PCR, lateral flow, immunoblots, immunofluorescence assays, immunoaffinity columns or card tests. RIDASCREEN®, RIDA®, PREP®, EASI EXTRACT, and PentoCheck® were worldwide recognized trademarks of R-Biopharm.

R-Biopharm has earned high accolades for its business performance. In 2004, the company achieved a double success, being nominated as a finalist for “Entrepreneur of the Year” 2004, 2005 and 2006 as well as being placed in 2004 and 2005 in the “Technology Fast 50”, a ranking of Germany’s 50 fastest-growing technology companies. Moreover, R-Biopharm received the “Sustainability Award” in the years 2012, 2013 and 2014.

More Less